Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 1.00 |
| ▸ | DRD2 | P14416 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22961532 | 1.00 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL21041845 | 0.95 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL21041528 | 0.95 | DRD3 (0.90) | DRD3DRD2 | |
| SCHEMBL22961718 | 0.91 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL22961554 | 0.91 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL22961432 | 0.90 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL22961567 | 0.90 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL21041033 | 0.90 | DRD3 (0.91) | DRD3DRD2 | |
| SCHEMBL21042024 | 0.90 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL21040740 | 0.90 | DRD3 (1.00) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578084-B2 | Condensed ring compounds having dopamine D3 receptor antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2023-02-14 | — | — | US | disclosed |
| US-20210040117-A1 | CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3744721-A1 | CONDENSED CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISM | Shionogi & Co., Ltd (JP) | 2020-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040117-A1 | CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | DRD3, DRD2, DRD1 | DRD3 1/4885DRD2 2/4885 |
| US-11578084-B2 | Condensed ring compounds having dopamine D3 receptor antagonistic effect | DRD3, DRD2, DRD1 | DRD3 1/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.